INVESTOR NEWS

  • Loading stock data...

Soaring Eagle Acquisition Corp. is a special purpose acquisition company founded by Harry Sloan, Jeff Sagansky, and Eli Baker.

Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds

Soaring Eagle Shareholder Approval Obtained, Closing Scheduled for September 16, 2021
Ginkgo Set to Begin Trading under NYSE: DNA on September 17, 2021

  • $1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction.
  • Investors were led by Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). Additional investors included ARK Investment Management LLC, ArrowMark Partners, Bain Capital Public Equity, Cascade Investment, Casdin Capital, Franklin Advisers, T. Rowe Price, and Viking Global Investors.
  • Business combination with Ginkgo approved by Soaring Eagle shareholders with 75% of shareholders participating in the vote and 97% voting in favor of the transaction.
    Read More

Soaring Eagle Announces Extraordinary General Meeting Date for Proposed Business Combination with Ginkgo

Extraordinary General Meeting Scheduled for September 14, 2021

NEW YORK, NY, August 13, 2021 – Soaring Eagle Acquisition Corp., a Cayman Islands exempted company limited by shares (the “Company” or “Soaring Eagle”) (Nasdaq: SRNG.U, SRNG, SRNG WS), announced today that it has scheduled the extraordinary general meeting of the Company’s shareholders (the “Special Meeting”) in connection with its business combination (the “Business Combination”) with Ginkgo Bioworks, Inc. to be held on September 14, 2021.  Notice of the Special Meeting and a proxy statement/prospectus in connection with the Special Meeting will be mailed to the Company’s shareholders of record as of the close of business on August 10, 2021 (the “Record Date”).

Read More

Ginkgo Bioworks and Soaring Eagle Acquisition Corp. Announce Effectiveness of Form S-4 Registration Statement

BOSTON and NEW YORK, Aug. 11, 2021 /PRNewswire/ — Ginkgo Bioworks (“Ginkgo”) and Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) (“Soaring Eagle”) announced today that the Securities and Exchange Commission (the “SEC”) has declared effective the Registration Statement on Form S-4 filed by Soaring Eagle with the SEC relating to the previously announced business combination between Ginkgo and Soaring Eagle (the “Business Combination”).

Read More

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

  • Collaboration aims to develop a next-generation AAV production platform to help accelerate Biogen’s efforts to bring novel gene therapies to patients worldwide
  • Ginkgo’s synthetic biology expertise may enable the expansion of therapeutic utility and overcome development challenges of viral vectors for gene therapy
  • Ginkgo to receive $5 million upfront payment and is eligible for up to $115 million in potential research, development, and commercial milestones

CAMBRIDGE, Mass. and BOSTON, Mass. — May 21, 2021 – Biogen (Nasdaq: BIIB) and Ginkgo Bioworks today announced a gene therapy collaboration. Together, the companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Read More

Ginkgo Bioworks to Become a Public Company and Expand its Leading Platform for Cell Programming

BOSTON, MA and LOS ANGELES, CA May 11, 2021 — Ginkgo Bioworks, Inc. (“Ginkgo”) and Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) (“Soaring Eagle”), a publicly traded special purpose acquisition company, have agreed to a business combination that will result in Ginkgo becoming a publicly-listed company.

Read More

Soaring Eagle Acquisition Corp., Led by Eagle Equity Partners’ Harry Sloan, Jeff Sagansky and Eli Baker Announces Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about April 19, 2021

NEW YORK, NY April 15, 2021 — Soaring Eagle Acquisition Corp. (the “Company”), the seventh public acquisition vehicle led by Eagle Equity Partners’ Harry Sloan, Jeff Sagansky and Eli Baker today announced that holders of the units sold in the Company’s initial public offering of 172,500,000 units completed on February 26, 2021

Read More

Soaring Eagle Acquisition Corp., Led by Eagle Equity Partners’ Harry Sloan, Jeff Sagansky and Eli Baker Announces Completion of $1.725 billion IPO

NEW YORK, NY February 26, 2021 — Soaring Eagle Acquisition Corp. (the “Company”), the seventh public acquisition vehicle led by Eagle Equity Partners’ Harry Sloan, Jeff Sagansky and Eli Baker today announced the closing of its initial public offering of 172,500,000 units, including 22,500,000 units issued pursuant to the exercise

Read More

Soaring Eagle Acquisition Corp., Led by Eagle Equity Partners’ Harry Sloan, Jeff Sagansky and Eli Baker Announces Pricing of $1.5 billion IPO

NEW YORK, NY February 23, 2021 — Soaring Eagle Acquisition Corp. (the “Company”), the seventh public acquisition vehicle led by Eagle Equity Partners’ Harry Sloan, Jeff Sagansky and Eli Baker today announced the pricing of its initial public offering of 150,000,000 units, at a price of $10.00 per unit. Each unit issued in the initial
Read More